Instead, it offers a framework for thinking through that decision based on the individual patient.

The two important questions to ask are, what is the reason for you to be on a GLP-1 receptor agonist? Someone might be on it for diabetes.

Someone might be on it for obesity.

Multiple reasons, right? So it's really important to understand what the reason is.

Once we have determined that there is a strong reason for someone to To be on that drug, the other important question to ask is, is there a hereditary syndrome at hand that we're looking at? If there is a strong indication and there is no hereditary cancer risk, then it is important to consider how is the neuroendocrine tumor doing? Are we dealing with a very large burden of disease? Are we dealing with progressive disease? Are we dealing with disease that has been associated with a lot of symptoms? Think if there's no hereditary cancer syndrome at play and there's a strong indication for patients to be on these agents.

and we're not dealing with worsening metastatic disease or progressive disease, and we're not dealing with a lot of symptom burden from your neuroendocrine tumor and neuroendocrine cancer, I think it's fair again to be on these agents.

But we just need to make sure we check all of our boxes before we do that.

And if a patient and their care team decide that a GLP-1 medication is appropriate, Dr. Graywell says careful dosing and monitoring become important parts of the plan.

Instead, it offers a framework for thinking through that decision based on the individual patient.

The two important questions to ask are, what is the reason for you to be on a GLP-1 receptor agonist? Someone might be on it for diabetes.

Someone might be on it for obesity.

Multiple reasons, right? So it's really important to understand what the reason is.

Once we have determined that there is a strong reason for someone to To be on that drug, the other important question to ask is, is there a hereditary syndrome at hand that we're looking at? If there is a strong indication and there is no hereditary cancer risk, then it is important to consider how is the neuroendocrine tumor doing? Are we dealing with a very large burden of disease? Are we dealing with progressive disease? Are we dealing with disease that has been associated with a lot of symptoms? Think if there's no hereditary cancer syndrome at play and there's a strong indication for patients to be on these agents.

and we're not dealing with worsening metastatic disease or progressive disease, and we're not dealing with a lot of symptom burden from your neuroendocrine tumor and neuroendocrine cancer, I think it's fair again to be on these agents.

But we just need to make sure we check all of our boxes before we do that.

And if a patient and their care team decide that a GLP-1 medication is appropriate, Dr. Graywell says careful dosing and monitoring become important parts of the plan.